Simultaneous Pharmacokinetic-Pharmacodynamic Modeling

Comparative Pharmacokinetics: Principles, Techniques, and Applications: Second Edition

Volumn , Issue , 2011, Pages 255-294

  Toutain, Pierre Louis ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Application of PK PD modeling to rational development of veterinary drugs, stressed; Classical parallel design for antiparasitic and antibiotic drugs; Dose effect relationship versus PK PD modeling; Final phase of modeling, and coupling of drug concentration active site to its biological and its clinical effects; Major modeling steps for PD components of model; PK PD modeling approach PK model, serving role of independent variables; PK PD modeling, explaining time course of drug effect; PK PD modeling, versatile tool in veterinary medicine, for selecting rational dosage regimens; Simultaneous pharmacokinetic pharmacodynamic modeling; Turnover models, incorporating submodel elements accounting for a placebo effect

Indexed keywords

EID: 84864074598     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470959916.ch13     Document Type: Chapter

References (45)

1. Aliabadi, F.S., and Lees, P. 2001. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. American Journal of Veterinary Research. 62: 1979-1989.
2. Aliabadi, F.S., and Lees, P. 2002. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics. 25: 161-174.
3. Atkinson, A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T., Spilker, B.A., Woodcock, J., and Zeger, S.L. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 69: 89-95.
4. Bonate, P.L. 2006. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer.
5. Botrel, M.A., Haak, T., Legrand, C., Concordet, D., Chevalier, R., and Toutain, P.L. 1994. Quantitative evaluation of an experimental inflammation induced with Freund's complete adjuvant in dogs. Journal of Pharmacology and Toxicology Methods. 32: 63-71.
6. Czock, D., and Keller, F. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. Journal of Pharmacokinetics and Pharmacodynamics. 34: 727-751.
7. D'Agata, E.M., Dupont-Rouzeyrol, M., Magal, P., Olivier, D., and Ruan, S. 2008. The impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteria. PLoS ONE. 3: e4036.
8. Dahl, S.G., Aarons, L., Gundert-Remy, U., Karlsson, M.O., Schneider, Y.J., Steimer, J.L., and Troconiz, I.F. 2009. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. Basic Clinical Pharmacology and Toxicology. 106: 2-12.
9. Danhof, M., de Lange, E.C., Della Pasqua, O.E., Ploeger, B.A., and Voskuyl, R.A. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences. 29: 186-191.
10. Dayneka, N.L., Garg, V., and Jusko, W.J. 1993. Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics. 21: 457-478.
11. Ette, E.I., Roy, A., and Nandy, P. 2007. Population pharmacokinetic/pharmacodynamic modeling of ordered categorical longitudinal data. In: Ette, E.I., and Williams, P.J. (eds.), Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons.
12. Fiedler-Kelly, B. 2007. PK/PD analysis of binary (logistic) outcome data. In: Ette, E.I., and Williams, P.J. (eds.), Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons.
13. Fosse, T.K., Toutain, P.L., Spadavecchia, C., Haga, H.A., Horsberg, T.E., and Ranheim, B. 2010. Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. Journal of Veterinary Pharmacology and Therapeutics (in press).
14. Frank, R., and Hargreaves, R. 2003. Clinical biomarkers in drug discovery and development. Nature Reviews Drug Discovery. 2: 566-580.
15. Friedman, P.A., and Hebert, S.C. 1997. Site and mechanism of diuretic action. In: Seldin, D., and Giebisch, G. (eds.), Diuretic Agents. Clinical Physiology and Pharmacology. San Diego, CA: Academic Press.
16. Gabrielsson, J., and Weiner, D. 2006. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Swedish Pharmaceutical Press.
17. Gardmark, M., Brynne, L., Hammarlund-Udenaes, M., and Karlsson, M.O. 1999. Interchangeability and predictive performance of empirical tolerance models. Clinical Pharmacokinetics. 36: 145-167.
18. Girard, P. 2005. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic and Clinical Pharmacology and Toxicology. 96: 228-234.
19. Girard, P., and Boissel, J.P. 1989. Clockwise hysteresis or proteresis. Journal of Pharmacokinetics and Biopharmaceutics. 17: 401-402.
20. Giraudel, J.M., Diquelou, A., Laroute, V., Lees, P., and Toutain, P.L. 2005. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. British Journal of Pharmacology. 146: 642-653.
21. Holford, N.H., and Sheiner, L.B. 1982. Kinetics of pharmacologic response. Pharmacology and Therapeutics. 16: 143-166.
22. Holford, N.H.G., and Ludden, T.M. 1994. Time course of drug effect. In: Welling, P.G., and Balant, L.P. (eds.), Pharmacokinetics of Drugs. Berlin: Springer-Verlag.
23. Jonker, D.M., Visser, S.A., van der Graaf, P.H., Voskuyl, R.A., and Danhof, M. 2005. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacology and Therapeutics. 106: 1-18.
24. Jusko, W.J., and Ko, H.C. 1994. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology and Therapeutics. 56: 406-419.
25. King, J.N., Maurer, M., and Toutain, P.L. 2003. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. Journal of Veterinary Pharmacology and Therapeutics. 26: 213-224.
26. KuKanich, B., and Papich, M.G. 2009. Opioid analgesic drugs. In: Riviere, J.E., and Papich, M.G. (eds.), Veterinary Pharmacology & Therapeutics, 9th Ed. Ames, IA: Wiley-Blackwell, pp. 301-336.
27. Lees, P., Giraudel, J., Landoni, M.F., and Toutain, P.L. 2004. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics. 27: 491-502.
28. Levy, G. 1964. Relationship between rate of elimination of tubocurarine and rate of decline of its pharmacological activity. British Journal of Anaesthesiology. 36: 694-695.
29. Levy, G. 1998. Impact of pharmacodynamic variability on drug delivery (1). Advanced Drug Delivery Reviews. 33: 201-206.
30. Mager, D.E., Wyska, E., and Jusko, W.J. 2003. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition. 31: 510-518.
31. Meibohm, B., and Derendorf, H. 2002. Pharmacokinetic/pharmacodynamic studies in drug product development. Journal of Pharmaceutical Sciences. 91: 18-31.
32. Monnoyer, S., Guyonnet, J., and Toutain, P.L. 2004. A preclinical pharmacokinetic/pharmacodynamic approach to determine a dose of GnRH, for treatment of ovarian follicular cyst in cattle. Journal of Veterinary Pharmacology and Therapeutics. 27: 527-535.
33. Mould, D.R. 2007. Developing models of disease progression. In: Ette, E.I., and Williams, P.J. (eds.), Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons.
34. Pillai, G., Gieschke, R., Goggin, T., Jacqmin, P., Schimmer, R.C., and Steimer, J.L. 2004. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. British Journal of Clinical Pharmacology. 58: 618-631.
35. Post, T.M., Freijer, J.I., DeJongh, J., and Danhof, M. 2005. Disease system analysis: basic disease progression models in degenerative disease. Pharmaceutical Research. 22: 1038-1049.
36. Qiao, G.L., and Fung, K.F. 1993. Pharmacokinetic-pharmacodynamic modelling of meperidine in goats (I): pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics. 16: 426-437.
37. Sheiner, L.B., Stanski, D.R., Vozeh, S., Miller, R.D., and Ham, J. 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clinical Pharmacology and Therapeutics. 25: 358-371.
38. Toutain, P.L., and Cester, C.C. 2004. Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint. American Journal of Veterinary Research. 65: 1533-1541.
39. Toutain, P.L., and Lees, P. 2004. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics. 27: 467-477.
40. Toutain, P.L., Autefage, A., Legrand, C., and Alvinerie, M. 1994. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. Journal of Veterinary Pharmacology and Therapeutics. 17: 459-469.
41. Toutain, P.L., Lefebvre, H.P., and King, J.N. 2000. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. Journal of Pharmacology and Experimental Therapeutics. 292: 1087-1093.
42. Toutain, P.L., Cester, C.C., Haak, T., and Laroute, V. 2001a. A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. Journal of Veterinary Pharmacology and Therapeutics. 24: 43-55.
43. Toutain, P.L., Cester, C.C., Haak, T., and Metge, S. 2001b. Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. Journal of Veterinary Pharmacology and Therapeutics. 24: 35-42.
44. Williams, P.J., and Ette, E.I. 2007. Biomarkers in drug development and pharmacometric modeling. In: Ette, E.I., and Williams, P.J. (eds.), Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons.
45. Zhi, J., Nightingale, C.H., and Quintiliani, R. 1986. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. Journal of Pharmaceutical Sciences. 75: 1063-1067.